Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Plus XELOX for HER2-positive Stage III Gastric Cancer
NCT02250209Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2014
- Primary completion
- Jun 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in gastric cancer (GC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02250209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250209.